Here Are the 3 Biggest Risks for Moderna Right Now

Moderna (NASDAQ: MRNA) wowed the stock market in March when it became the first to enter human testing with its investigational coronavirus vaccine. The shares got another boost when the clinical-stage biotech company announced encouraging interim phase 1 trial results. The vaccine has since entered phase 2 studies, and a phase 3 trial is expected to begin next month.

Though the coronavirus vaccine development path has been steady for Moderna, risks still lie ahead. As the company approaches its late-stage trial, here are the three biggest risks that could throw the program off track, and therefore, hurt Moderna share performance:

Image source: Getty Images.

Source Fool.com